Molecular Partners

Molecular Partners is a biopharmaceutical company that specializes in the research, development, and commercialization of therapeutic proteins known as DARPin therapeutics. These proteins are designed to have specific binding properties and can be used in a variety of therapeutic applications, including oncology, ophthalmology, and immunology.

History

Molecular Partners was founded in 2004 by a group of scientists from the University of Zurich. The company's initial focus was on the development of DARPin therapeutics, a new class of protein therapeutics that offer several advantages over traditional antibodies.

DARPin Therapeutics

DARPin therapeutics are a new class of protein therapeutics that are based on the natural protein architecture of ankyrin repeat proteins. These proteins are characterized by their small size, high stability, and the ability to bind to a wide range of targets with high specificity and affinity.

DARPin therapeutics have several advantages over traditional antibodies. They are smaller, which allows them to penetrate tissues more effectively. They are also more stable, which means they can be stored and administered more easily. Furthermore, they can be engineered to bind to multiple targets simultaneously, which could potentially make them more effective in treating complex diseases.

Research and Development

Molecular Partners is currently developing several DARPin therapeutics for various indications. These include MP0250, a multi-DARPin therapeutic for the treatment of multiple myeloma, and MP0274, a single-DARPin therapeutic for the treatment of HER2-positive breast cancer.

The company is also exploring the potential of DARPin therapeutics in other areas, such as ophthalmology and immunology. For example, it is developing MP0112, a DARPin therapeutic for the treatment of age-related macular degeneration, and MP0310, a DARPin therapeutic for the treatment of autoimmune diseases.

See Also

• Protein therapeutics
• Ankyrin repeat proteins
• Multiple myeloma
• HER2-positive breast cancer
• Age-related macular degeneration
• Autoimmune diseases

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!